公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2005 | Gefitinib treatment for non-small cell lung cancer - A study including patients with poor performance status | Su W.-P.; CHIH-HSIN YANG ; CHONG-JEN YU ; JIN-YUAN SHIH ; CHIUN HSU ; PAN-CHYR YANG | Journal of the Formosan Medical Association | 12 | 10 | |
2002 | Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer | CHIH-HSIN YANG ; PAN-CHYR YANG ; Wang L.S.; Lee Y.C.; CHIEN-JEN CHANG ; Lui L.T.; Yen S.H.; CHIUN HSU ; ANN-LII CHENG ; Liu M.Y.; Chiang S.C.; Chen Y.M.; KWEN-TAY LUH ; Huang M.H.; Yang P.-C.; Perng R.-P. | British Journal of Cancer | 24 | 20 | |
2015 | Gemcitabine plus cisplatin for advanced biliary tract cancer: A systematic review | Park J.O.; Oh D.-Y.; CHIUN HSU ; Chen J.-S.; Chen L.-T.; Orlando M.; Kim J.S.; Lim H.Y. | Cancer Research and Treatment | 63 | 58 | |
2008 | Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma-A randomized phase II trial | CHIUN HSU ; SUNG-HSIN KUO ; Hu F.-C.; ANN-LII CHENG ; JIN-YUAN SHIH ; CHONG-JEN YU ; CHIA-CHI LIN ; Huang T.-C.; PAN-CHYR YANG ; CHIH-HSIN YANG | Lung Cancer | 14 | 11 | |
2023 | Genomic and Transcriptomic Landscape of an Oral Squamous Cell Carcinoma Mouse Model for Immunotherapy | Lee, Yi-Mei; Hsu, Chia-Lang; Chen, Yu-Hsin; DA-LIANG OU ; CHIUN HSU ; Tan, Ching-Ting | Cancer immunology research | | | |
2012 | Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: A meta-analysis and meta-regression | CHIUN HSU ; Ying-Chun Shen ; Cheng C.-C.; ANN-LII CHENG ; Hu F.-C.; KUN-HUEI YEH | Gastric Cancer | 19 | 18 | |
2010 | Geographic difference in survival outcome for advanced hepatocellular carcinoma: Implications on future clinical trial design | CHIUN HSU ; Ying-Chun Shen ; Cheng C.-C.; Hu F.-C.; ANN-LII CHENG | Contemporary Clinical Trials | 41 | 37 | |
2015 | Growth arrest dna damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma | DA-LIANG OU ; Shyue S.-K.; LIANG-IN LIN ; Feng Z.-R.; Liou J.-Y.; Fan H.-H.; Lee B.-S.; CHIUN HSU ; ANN-LII CHENG | Oncotarget | 12 | 9 | |
2014 | H3K9 histone methyltransferase, KMT1E/SETDB1, Cooperates with the SMAD2/3 pathway to suppress lung cancer metastasis | Wu P.-C.; Lu J.-W.; Yang J.-Y.; Lin I.-H.; DA-LIANG OU ; Lin Y.-H.; Chou K.-H.; Huang W.-F.; Wang W.-P.; Huang Y.-L.; CHIUN HSU ; LIANG-IN LIN ; Lin Y.-M.; James Shen C.-K.; Tzeng T.-Y. | Cancer Research | 54 | 53 | |
2014 | Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: A distinct entity with lower aggressiveness and higher chemosensitivity | SUNG-HSIN KUO ; KUN-HUEI YEH ; Chen L.-T.; CHUNG-WU LIN ; PING-NING HSU ; CHIUN HSU ; MING-SHIANG WU ; Tzeng Y.-S.; Tsai H.-J.; HSIU-PO WANG ; ANN-LII CHENG | Blood Cancer Journal | 34 | 32 | |
2023 | Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab | CHIUN HSU ; Ducreux, Michel; Zhu, Andrew X; Qin, Shukui; Ikeda, Masafumi; Kim, Tae-You; Galle, Peter R; Finn, Richard S; Chen, Ethan; Ma, Ning; Hu, Youyou; Li, Lindong; ANN-LII CHENG | Liver cancer | 1 | 0 | |
2014 | Hepatitis B and C viruses are not risks for pancreatic adenocarcinoma | MING-CHU CHANG ; CHIEN-HUNG CHEN ; JA-DER LIANG ; YU-WEN TIEN ; CHIUN HSU ; Wong J.-M.; YU-TING CHANG | World Journal of Gastroenterology | 21 | 20 | |
2013 | Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: Analysis from the Asia Lymphoma Study Group | Kim S.J.; CHIUN HSU ; Song Y.-Q.; Tay K.; Hong X.-N.; Cao J.; Kim J.S.; Eom H.S.; Lee J.H.; Zhu J.; Chang K.-M.; Reksodiputro A.H.; Tan D.; Goh Y.T.; Lee J.; Intragumtornchai T.; Chng W.-J.; ANN-LII CHENG ; Lim S.T.; Suh C.; Kwong Y.-L.; Kim W.S. | European Journal of Cancer | 98 | 90 | |
2002 | HER-2/neu overexpression is rare in hepatocellular carcinoma and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity | CHIUN HSU ; Huang C.-L.; Hsu H.-C.; PO-HUANG LEE ; Wang S.-J.; ANN-LII CHENG | Cancer | 41 | 33 | |
2011 | High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy | YU-YUN SHAO ; ZHONG-ZHE LIN ; Chen T.-J.; CHIUN HSU ; Ying-Chun Shen ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncology | 17 | 17 | |
2018 | Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy | Lin Y.-Y.; CHING-TING TAN ; Chen C.-W.; DA-LIANG OU ; ANN-LII CHENG ; CHIUN HSU | Seminars in Liver Disease | 62 | 53 | |
2021 | Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab | CHIUN HSU ; Rimassa L.; Sun H.-C.; Vogel A.; Kaseb A.O. | Therapeutic Advances in Medical Oncology | 16 | 14 | |
2011 | Increased expression of 14-3-3β promotes tumor progression and predicts extrahepatic metastasis and worse survival in hepatocellular carcinoma | Liu T.-A.; Jan Y.-J.; BOR-SHENG KO ; Chen S.-C.; Liang S.-M.; Hung Y.-L.; CHIUN HSU ; TANG-LONG SHEN ; Lee Y.-M.; Chen P.-F.; Wang J.; Shyue S.-K.; Liou J.-Y. | American Journal of Pathology | 39 | 38 | |
2009 | Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma | DA-LIANG OU ; Ying-Chun Shen ; JA-DER LIANG ; Liou J.-Y.; SUNG-LIANG YU ; Fan H.-H.; Wang D.-S.; YEN-SHEN LU ; CHIUN HSU ; ANN-LII CHENG | Clinical Cancer Research | 32 | 34 | |
2010 | Induction of DNA damage-inducible gene GADD45β contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells | DA-LIANG OU ; Ying-Chun Shen ; SUNG-LIANG YU ; Chen K.-F.; Yeh P.-Y.; Fan H.-H.; Feng W.-C.; Wang C.-T.; LIANG-IN LIN ; CHIUN HSU ; ANN-LII CHENG | Cancer Research | 70 | 69 | |